I+Ve got a question: how long should we treat relapsed CLL?

Affiliations

Editorial

Moritz Fürstenau. Blood. 2025.

. 2025 May 29;145(22):2536-2538.

doi: 10.1182/blood.2025028679.

¹ Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and University of Cologne.

No abstract available

Comment on

Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trial.
Condoluci A, Romano I, Dietrich D, Pini K, Stüssi G, Müller G, Cantoni N, Cathomas R, Mey U, Widmer A, Zenz T, Gregor M, Heim D, Andres M, Benz R, Rossi D. Condoluci A, et al. Blood. 2025 May 29;145(22):2587-2598. doi: 10.1182/blood.2024026879. Blood. 2025. PMID: 40009495 Clinical Trial.